Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jul;133(5):687-94.
doi: 10.1038/sj.bjp.0704131.

Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats

Affiliations

Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozotocin-diabetic rats

G Miric et al. Br J Pharmacol. 2001 Jul.

Abstract

Fibrosis leads to chronic impairment of cardiac and renal function and thus reversal of existing fibrosis may improve function and survival. This project has determined whether pirfenidone, a new antifibrotic compound, and spironolactone, an aldosterone antagonist, reverse both deposition of the major extracellular matrix proteins, collagen and fibronectin, and functional changes in the streptozotocin(STZ)-diabetic rat. Streptozotocin (65 mg kg(-1) i.v.)-treated rats given pirfenidone (5-methyl-1-phenyl-2-[1H]-pyridone; approximately 200 mg kg(-1) day(-1) as 0.2 - 2g 1(-1) drinking water) or spironolactone (50 mg kg(-1) day(-1) s.c.) for 4 weeks starting 4 weeks after STZ showed no attenuation of the increased blood glucose concentrations and increased food and water intakes which characterize diabetes in this model. STZ-treatment increased perivascular and interstitial collagen deposition in the left ventricle and kidney, and surrounding the aorta. Cardiac, renal and plasma fibronectin concentrations increased in STZ-diabetic rats. Passive diastolic stiffness increased in isolated hearts from STZ-diabetic rats. Both pirfenidone and spironolactone treatment attenuated these increases without normalizing the decreased +dP/dt(max) of STZ-diabetic hearts. Left ventricular papillary muscles from STZ-treated rats showed decreased maximal positive inotropic responses to noradrenaline, EMD 57033 (calcium sensitizer) and calcium chloride; this was not reversed by pirfenidone or spironolactone treatment. STZ-treatment transiently decreased GFR and urine flow rates in isolated perfused kidneys; pirfenidone but not spironolactone prevented the return to control values. Thus, short-term pirfenidone and spironolactone treatment reversed cardiac and renal fibrosis and attenuated the increased diastolic stiffness without normalizing cardiac contractility or renal function in STZ-diabetic rats.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Body weight (A), daily water intake (B) and food intake (C) for control (open circle), control+pirfenidone (open triangle), control+spironolactone (open square), STZ (filled circle), STZ+pirfenidone (filled triangle) and STZ+spironolactone (filled square) rats.
Figure 2
Figure 2
Daily pirfenidone dose in control+pirfenidone (open triangles) and STZ+pirfenidone (filled triangles) rats.
Figure 3
Figure 3
Collagen distribution in the left ventricle (A), thoracic aorta (B) and kidney (C) of control (C), control+pirfenidone (CP), control+spironolactone (CSp), STZ (S), STZ+pirfenidone (SP) and STZ+spironolactone (SSp) rats; n=6 [* P<0.05 vs C; ** P<0.05 vs S].
Figure 4
Figure 4
Fibronectin concentration in the left ventricle (A), kidney (B) and plasma (C) of control (C), control+pirfenidone (CP), control+spironolactone (CSp), STZ (S), STZ+pirfenidone (SP) and STZ+spironolactone (SSp) rats; n=6 [* P<0.05 vs C; ** P<0.05 vs S].
Figure 5
Figure 5
Cumulative concentration-response curves for noradrenaline and calcium chloride (A) and EMD 57033 (B) in left ventricular papillary muscles from control (C, open circles) (n=8), STZ (S, filled circles) (n=8), STZ+pirfenidone (SP, filled triangles) (n=8) and STZ+spironolactone (SSp, filled squares) (n=8) rats. [*p<0.05 vs C].
Figure 6
Figure 6
Concentration-response curves for noradrenaline in right atria (n=8) from control (C, open circles), STZ (S, filled circles), STZ+pirfenidone (SP, filled triangles) and STZ+spironolactone (SSp, filled squares) rats.
Figure 7
Figure 7
Concentration-response curves for noradrenaline in thoracic aortic rings (n=8) from control (C, open circles), STZ (S, filled circles), STZ+pirfenidone (SP, filled triangles) and STZ+spironolactone (SSp, filled squares) rats.
Figure 8
Figure 8
Glomerular filtration rates (A), urine flow rates (B), renal arterial flow (C) and fractional excretion of sodium (D) (n=6) in isolated perfused kidneys from control (C, open circles), STZ (4 weeks after STZ, S4, filled diamonds; 8 weeks after STZ, S8, filled circles), STZ+pirfenidone (SP, filled triangles) and STZ+spironolactone (SSp, filled squares) rats.

References

    1. ASSAYAG P., CARRÉ F., CHEVALIER B., DELCAYRE C., MANSIER P., SWYNGHEDAUW B. Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis. Cardiovasc. Res. 1997;34:439–444. - PubMed
    1. BENETOS A., LACOLLEY P., SAFAR M.E. Prevention of aortic fibrosis by spironolactone in spontaneously hypertensive rats. Arterioscler. Thromb. Vasc. Biol. 1997;17:1152–1156. - PubMed
    1. BRILLA C.G., WEBER K.T. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc. Res. 1992;26:671–677. - PubMed
    1. BROWN L., CRAGOE E.J., JR, ABEL K.C., MANLEY S.W., BOURKE J.R. Amiloride analogues induce responses in isolated rat cardiovascular tissues by inhibition of Na+/Ca2+ exchange. Naunyn-Schmiedeberg's Arch. Pharmacol. 1991b;344:220–224. - PubMed
    1. BROWN L., DUCE B., MIRIC G., SERNIA C. Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J. Am. Soc. Nephrol. 1999;10:S143–S148. - PubMed

MeSH terms

LinkOut - more resources